Table 4.
Analysis of occupational disease-specific AOPs
| AOPs | MIEs (No.) | KEs (No.) | AOs (No.) |
|---|---|---|---|
| AOP 200 Estrogen receptor activation leading to breast cancer | 1181 |
1182 1183 177 1088 1187 1188 1189 1190 1191 1192 1194 1195 1196 1197 1198 1213 1239 1240 1241 1242 |
1193 |
| AOP 293 Increased DNA damage leading to increased risk of breast cancer | 1194 |
1492 1493 1632 1494 1182 |
185 1192 1193 |
| AOP 294 Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | 1632 |
1182 1492 1493 1494 |
1194 185 1192 1193 |
| AOP 66 Modulation of Adult Leydig Cell Function Subsequent Glucocorticoid Activation in the Fetal Testis |
653 654 |
655 656 657 |
505 |
| AOP 67 Modulation of Adult Leydig Cell Function Subsequent to Estradiaol Activation in the Fetal Testis |
658 659 |
655 660 656 |
505 |
| AOP 68 Modulation of Adult Leydig Cell Function Subsequent to Alterations in the Fetal Testis Protome | 661 |
655 657 656 |
505 |
| AOP 107 Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | 715 |
1214 716 774 |
719 |
| AOP 108 Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | 724 |
768 209 726 769 |
719 |
| AOP 117 Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | 785 |
716 774 |
719 |
| AOP 118 Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | 786 |
787 774 |
719 |
| AOP 37 PPARalpha-dependent liver cancer | 227 |
1170 716 1171 |
719 |
| AOP 153 Aromatase inhibition leading to ovulation inhibition and decreased fertility in female rats | 964 |
965 966 967 968 969 970 971 |
972 |
| AOP 345 Androgen receptor (AR) antagonism leading to decreased fertility in females | 26 |
286 971 |
972 |